pmid	doi	year	title	Hugo_Symbol
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	TP53
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	TP53
33954816	10.1007/s00277-021-04530-y	2022	Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.	TP53
34092056	10.3324/haematol.2021.278304	2022	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.	TP53
34226971	10.1007/s00428-021-03148-9	2022	Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.	TP53
34244612	10.1038/s41375-021-01311-4	2022	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.	TP53
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	TP53
34319003	10.1002/cnr2.1524	2022	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.	TP53
34332791	10.1016/j.pathol.2021.04.008	2022	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	TP53
34365516	10.1007/s00262-021-03009-z	2022	Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.	TP53
34467833	10.1080/10428194.2021.1973670	2022	CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.	TP53
34528662	10.1093/ajcp/aqab105	2022	MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.	TP53
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	TP53
34592901	10.1080/10428194.2021.1983568	2022	Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.	TP53
34597466	10.1002/pbc.29361	2022	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.	TP53
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	TP53
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	TP53
34673251	10.1016/j.cbpc.2021.109215	2022	Environmentally relevant lead (Pb) water concentration induce toxicity in zebrafish (Danio rerio) larvae.	TP53
34675373	10.1038/s41375-021-01444-6	2022	Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.	TP53
34687488	10.1002/gcc.23005	2022	Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.	TP53
34687742	10.1016/j.jid.2021.09.024	2022	PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression.	TP53
34690091	10.1016/j.clml.2021.09.013	2022	Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.	TP53
34699592	10.1182/blood.2021011895	2022	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.	TP53
34710245	10.1002/ajh.26392	2022	Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma.	TP53
34728235	10.1016/j.bbamcr.2021.119168	2022	DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.	TP53
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	TP53
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	TP53
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	TP53
34799485	10.1097/PAS.0000000000001834	2022	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.	TP53
34808593	10.1016/j.cancergen.2021.10.003	2022	Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.	TP53
34818414	10.1182/blood.2021012734	2022	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.	TP53
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	TP53
34860572	10.1200/JCO.21.02143	2022	Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.	TP53
34861096	10.1002/1878-0261.13153	2022	Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.	TP53
34861697	10.1182/bloodadvances.2021006156	2022	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.	TP53
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	TP53
34907000	10.1124/molpharm.121.000354	2022	Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.	TP53
34928233	10.5152/balkanmedj.2021.21068	2022	HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression	TP53
34933652	10.1080/10428194.2021.2018579	2022	Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.	TP53
34941996	10.1182/bloodadvances.2021005954	2022	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.	TP53
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	TP53
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	TP53
34998786	10.1016/j.clml.2021.12.008	2022	The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.	TP53
35004079	10.7759/cureus.20914	2022	The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia.	TP53
35014928	10.1080/10428194.2021.2020779	2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.	TP53
35030036	10.1200/JCO.21.02321	2022	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.	TP53
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	TP53
35042152	10.1016/j.esmoop.2021.100333	2022	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.	TP53
35047863	10.1016/j.xhgg.2021.100078	2022	A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.	TP53
35071774	10.1515/med-2021-0409	2022	The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma.	TP53
35072373	10.1097/PPO.0000000000000573	2022	Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.	TP53
35091682	10.1038/s41388-022-02196-y	2022	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.	TP53
35101379	10.1016/j.clml.2022.01.002	2022	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).	TP53
35105854	10.1038/s41408-022-00617-5	2022	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.	TP53
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	TP53
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	TP53
35130959	10.1186/s40364-022-00352-w	2022	Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma.	TP53
35132678	10.1002/ajh.26490	2022	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.	TP53
35151528	10.1016/j.blre.2022.100930	2022	CLL update 2022: A continuing evolution in care.	TP53
35184869	10.1016/j.revmed.2022.01.010	2022	[Chronic lymphocytic leukemia].	TP53
35203244	10.3390/cells11040593	2022	Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.	TP53
35231988	10.3760/cma.j.issn.0253-2727.2022.01.005	2022	[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].	TP53
35232479	10.1186/s13046-022-02269-6	2022	Partial p53 reactivation is sufficient to induce cancer regression.	TP53
35237397	10.1177/20406207221080743	2022	Mantle cell lymphoma management trends and novel agents: where are we going?	TP53
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	TP53
35264779	10.1038/s41418-022-00964-7	2022	Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence.	TP53
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	TP53
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	TP53
35280362	10.21037/atm-22-412	2022	Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer.	TP53
35280829	10.3389/fonc.2022.811151	2022	Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing.	TP53
35301414	10.1038/s41379-022-01022-w	2022	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.	TP53
35327381	10.3390/biomedicines10030579	2022	Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma.	TP53
35344582	10.1182/blood.2021014007	2022	Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.	TP53
35356636	10.14740/jh942	2022	Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.	TP53
35371098	10.3389/fimmu.2022.858590	2022	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.	TP53
35380239	10.1007/s00277-022-04806-x	2022	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.	TP53
35399106	10.1038/s41392-022-00924-0	2022	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.	TP53
35417939	10.3324/haematol.2021.280352	2022	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.	TP53
35426613	10.1007/s00432-022-04022-0	2022	Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.	TP53
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	TP53
35437610	10.1007/s00277-022-04795-x	2022	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.	TP53
35437925	10.1002/cam4.4663	2022	Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.	TP53
35452696	10.1016/j.humpath.2022.04.002	2022	B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas.	TP53
35459873	10.1038/s41375-022-01571-8	2022	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.	TP53
35486574	10.1371/journal.pone.0267543	2022	Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.	TP53
35490155	10.1016/j.clml.2022.04.001	2022	Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway.	TP53
35503707	10.1080/10428194.2022.2070911	2022	Rare case of leptomeningeal small lymphocytic lymphoma with <i>TP53</i> mutation detected by deep next-generation sequencing.	TP53
35511481	10.1080/09553002.2022.2074164	2022	<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines.	TP53
35533245	10.1158/2643-3230.BCD-21-0177	2022	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.	TP53
35543621	10.1080/10428194.2022.2070913	2022	Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.	TP53
35551107	10.5045/br.2022.2020113	2022	Smudge cells in CD200<sup>+</sup>, <i>TP53</i> mutated leukemic mantle cell lymphoma.	TP53
35551110	10.5045/br.2022.2022052	2022	Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease.	TP53
35561299	10.1200/EDBK_349509	2022	New Directions for Mantle Cell Lymphoma in 2022.	TP53
35561314	10.1182/bloodadvances.2022007247	2022	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.	TP53
35562412	10.1038/s41379-022-01085-9	2022	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.	TP53
35577753	10.1016/j.clml.2022.04.017	2022	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	TP53
35579989	10.1002/ijc.34123	2022	Special issue The advance of solid tumor research in China: Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.	TP53
35585141	10.1038/s41375-022-01587-0	2022	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.	TP53
35592333	10.3389/fimmu.2022.888250	2022	Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma.	TP53
35592856	10.3389/fmed.2022.808378	2022	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.	TP53
35598475	10.1016/j.leukres.2022.106857	2022	De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.	TP53
35609408	10.1016/j.lungcan.2022.05.002	2022	Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.	TP53
35616090	10.1002/cam4.4834	2022	Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.	TP53
35624058	10.1016/j.clml.2022.04.007	2022	Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.	TP53
35628297	10.3390/ijms23105486	2022	Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach.	TP53
35635647	10.1007/s10534-022-00397-2	2022	TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.	TP53
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	TP53
35671390	10.1182/blood.2021015135	2022	The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.	TP53
35674998	10.1007/s11899-022-00663-7	2022	Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.	TP53
35681513	10.3390/cells11111818	2022	A Unique Spectrum of Spontaneous Tumors in <i>Dino</i> Knockout Mice Identifies Tissue-Specific Requirements for Tumor Suppression.	TP53
35681698	10.3390/cancers14112720	2022	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib.	TP53
35705773	10.1007/s11033-022-07643-3	2022	Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.	TP53
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	TP53
35719104	10.1080/10428194.2022.2087070	2022	TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.	TP53
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	TP53
35727053	10.1002/cncr.34348	2022	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	TP53
35757723	10.3389/fimmu.2022.894787	2022	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.	TP53
35760783	10.1038/s41419-022-05021-2	2022	IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.	TP53
35761419	10.1186/s40164-022-00292-z	2022	Targeting metabolic reprogramming in chronic lymphocytic leukemia.	TP53
35779323	10.1016/j.tranon.2022.101471	2022	Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations.	TP53
35785159	10.3389/fonc.2022.813158	2022	Genomic Features of Solid Tumor Patients Harboring <i>ALK/ROS1/NTRK</i> Gene Fusions.	TP53
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	TP53
35829664	10.1111/bjh.18352	2022	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	TP53
35835991	10.1038/s41375-022-01634-w	2022	APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.	TP53
35846192	10.1002/jha2.354	2022	T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone.	TP53
35852680	10.1007/s12094-022-02884-x	2022	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.	TP53
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	TP53
35872366	10.1016/j.prp.2022.154033	2022	Association of ATG16L1 rs2241880 and TP53 rs1042522 with characteristics and course of diffuse large B-cell lymphoma.	TP53
35879233	10.1111/imj.15851	2022	Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.	TP53
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	TP53
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	TP53
35908104	10.1038/s41375-022-01655-5	2022	Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.	TP53
35910501	10.6004/jadpro.2022.13.5.7	2022	An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.	TP53
35940055	10.1016/j.ejca.2022.06.037	2022	First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.	TP53
35941212	10.1038/s41375-022-01649-3	2022	A phase two study of high dose blinatumomab in Richter's syndrome.	TP53
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	TP53
35963941	10.1038/s41375-022-01658-2	2022	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.	TP53
35964234	10.1093/ajcp/aqac087	2022	Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.	TP53
35967131	10.7759/cureus.26738	2022	Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.	TP53
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	TP53
36017149	10.1155/2022/7904293	2022	Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia.	TP53
36029002	10.1111/bjh.18419	2022	Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.	TP53
36029326	10.1007/s00277-022-04914-8	2022	Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.	TP53
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	TP53
36059252	10.1080/10428194.2022.2116932	2022	MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.	TP53
36059262	10.1080/10428194.2022.2118529	2022	p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.	TP53
36059700	10.3389/fonc.2022.976762	2022	Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.	TP53
36065483	10.1111/cas.15522	2022	Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk.	TP53
36075047	10.1080/10428194.2022.2118532	2022	A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.	TP53
36089905	10.1080/10428194.2022.2118533	2022	Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatment.	TP53
32193631	10.1007/s00277-020-03974-y	2021	Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.	TP53
32356355	10.1002/ajh.25848	2021	Triple hit SOX11<sup>-</sup> , MME<sup>+</sup> , TP53 mutated high-grade pleomorphic mantle cell lymphoma.	TP53
32488603	10.1007/s00277-020-04094-3	2021	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.	TP53
32732362	10.3324/haematol.2020.254276	2021	Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.	TP53
32908255	10.1038/s41379-020-00669-7	2021	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.	TP53
32924682	10.1080/10428194.2020.1817441	2021	The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.	TP53
32946634	10.1111/his.14256	2021	Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung.	TP53
32958587	10.1158/1940-6207.CAPR-20-0368	2021	Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.	TP53
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	TP53
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	TP53
33040459	10.1002/1878-0261.12822	2021	EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.	TP53
33087830	10.1038/s41375-020-01061-9	2021	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.	TP53
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	TP53
33154093	10.1158/1541-7786.MCR-20-0466	2021	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.	TP53
33179373	10.1002/iub.2407	2021	Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer.	TP53
33183999	10.1016/j.cancergen.2020.10.003	2021	FANCA, TP53, and del(5q)/RPS14 alterations in a patient with T-cell non-Hodgkin lymphoma and concomitant Fanconi anemia and Li-Fraumeni syndrome.	TP53
33199185	10.1016/j.clml.2020.10.012	2021	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.	TP53
33237469	10.1007/s00428-020-02971-w	2021	ALK alterations in salivary gland carcinomas.	TP53
33241658	10.1111/jcmm.16117	2021	Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin.	TP53
33247178	10.1038/s41375-020-01093-1	2021	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.	TP53
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	TP53
33277788	10.1002/gcc.22925	2021	Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant.	TP53
33303420	10.1016/j.clml.2020.10.009	2021	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.	TP53
33306126	10.1093/jmcb/mjaa065	2021	BCL7C suppresses ovarian cancer growth by inactivating mutant p53.	TP53
33310890	10.1158/1078-0432.CCR-20-2853	2021	Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression.	TP53
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	TP53
33314017	10.1111/bjh.17141	2021	Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.	TP53
33316538	10.1016/j.neo.2020.11.010	2021	U-RT1 - A new model for Richter transformation.	TP53
33328584	10.1038/s41568-020-00315-z	2021	Advances in germline predisposition to acute leukaemias and myeloid neoplasms.	TP53
33364550	10.1097/HS9.0000000000000510	2021	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.	TP53
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	TP53
33399480	10.1080/10428194.2020.1864354	2021	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis.	TP53
33414134	10.1158/1078-0432.CCR-20-2378	2021	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.	TP53
33414171	10.1158/0008-5472.CAN-20-1504	2021	CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.	TP53
33454909	10.1007/s11033-021-06136-z	2021	Deciphering the molecular pathways of apoptosis using purified fractions from leaf extract of Basella alba through studying the regulation of apoptosis related genes.	TP53
33486679	10.1007/s11060-020-03676-5	2021	Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.	TP53
33494549	10.3390/ph14020080	2021	Therapeutic Sequencing in ALK<sup>+</sup> NSCLC.	TP53
33495922	10.1007/s00277-021-04419-w	2021	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.	TP53
33507515	10.1007/s11899-021-00605-9	2021	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.	TP53
33509276	10.1186/s13148-021-01011-x	2021	Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.	TP53
33528622	10.1007/s00428-021-03022-8	2021	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.	TP53
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	TP53
33542453	10.1038/s41598-021-82867-0	2021	Significance of abnormal 53BP1 expression as a novel molecular pathologic parameter of follicular-shaped B-cell lymphoid lesions in human digestive tract.	TP53
33546774	10.1186/s40164-021-00200-x	2021	Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.	TP53
33561953	10.3390/cancers13040650	2021	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.	TP53
33563892	10.1038/s41392-020-00412-3	2021	Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.	TP53
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	TP53
33569988	10.1080/10428194.2021.1876871	2021	MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma.	TP53
33588113	10.1016/j.jtho.2021.01.1615	2021	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.	TP53
33615665	10.1002/iub.2453	2021	Mitochondrial-nuclear p53 trafficking controls neuronal susceptibility in stroke.	TP53
33618247	10.1016/j.prp.2021.153370	2021	Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.	TP53
33631112	10.1016/S2352-3026(20)30433-6	2021	Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.	TP53
33631963	10.1177/0963689721996649	2021	Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.	TP53
33634864	10.1002/ijc.33527	2021	Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.	TP53
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	TP53
33660365	10.1111/acel.13331	2021	A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition.	TP53
33679144	10.1177/2634853521994094	2021	A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and Literature Review.	TP53
33687951	10.1158/0008-5472.CAN-21-0033	2021	Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations.	TP53
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.	TP53
33742045	10.1038/s41598-021-85354-8	2021	Short and long-read genome sequencing methodologies for somatic variant detection; genomic analysis of a patient with diffuse large B-cell lymphoma.	TP53
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	TP53
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	TP53
33757561	10.1186/s13104-021-05521-y	2021	HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL).	TP53
33759673	10.1080/17474086.2021.1908121	2021	Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	TP53
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	TP53
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	TP53
33808787	10.3390/cancers13061414	2021	EBV and the Pathogenesis of NK/T Cell Lymphoma.	TP53
33851417	10.1111/bjh.17394	2021	Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.	TP53
33867306	10.1016/j.clml.2021.03.003	2021	Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma.	TP53
33872109	10.1177/10935266211007254	2021	Distinctive Clinicopathologic Features of Monomorphic B-cell Post-transplant Lymphoproliferative Disorders in Children.	TP53
33889527	10.21037/tlcr-21-160	2021	Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.	TP53
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	TP53
33902046	10.1159/000514648	2021	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.	TP53
33902665	10.1186/s13045-021-01054-w	2021	Current and future treatment strategies in chronic lymphocytic leukemia.	TP53
33903686	10.1038/s41598-021-88449-4	2021	Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients.	TP53
33904352	10.1080/10428194.2021.1919663	2021	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, <i>TP53</i> deletion, and <i>TP53</i> mutations.	TP53
33918002	10.3390/genes12040539	2021	Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells.	TP53
33938069	10.1002/gcc.22956	2021	Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia.	TP53
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	TP53
33946435	10.3390/cancers13092167	2021	Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.	TP53
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	TP53
33972504	10.1038/s41408-021-00477-5	2021	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	TP53
33981772	10.1155/2021/7463867	2021	Circular RNA circPVT1 Contributes to Doxorubicin (DXR) Resistance of Osteosarcoma Cells by Regulating TRIAP1 via miR-137.	TP53
33987937	10.1002/iub.2503	2021	Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.	TP53
33988304	10.1111/ijlh.13577	2021	Karyotypic complexity, TP53 pathogenic variants, and increased number of variants on Next-Generation Sequencing are associated with disease progression in a North American Adult T-Cell Leukemia/Lymphoma cohort.	TP53
34010787	10.1016/j.ejca.2021.03.034	2021	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.	TP53
34049842	10.1016/j.clml.2020.10.001	2021	Case Report of an Unusual Tumor in an Adult With a TP53 Germline Mutation.	TP53
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	TP53
34066756	10.3390/diagnostics11050844	2021	<i>TP53</i>-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.	TP53
34074652	10.1101/mcs.a006089	2021	Twists and turns from tumor in tumor profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.	TP53
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	TP53
34080325	10.1002/cam4.4024	2021	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.	TP53
34080947	10.1080/10428194.2021.1933480	2021	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.	TP53
34088885	10.18632/aging.203098	2021	Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.	TP53
34099776	10.1038/s41598-021-91433-7	2021	Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.	TP53
34110383	10.1001/jamaoncol.2021.1649	2021	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.	TP53
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	TP53
34115827	10.1182/blood.2020009655	2021	Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.	TP53
34150491	10.1016/j.lrr.2021.100255	2021	Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma.	TP53
34164264	10.21037/tlcr-21-32	2021	Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.	TP53
34174984	10.1016/j.hoc.2021.04.001	2021	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.	TP53
34175504	10.1016/j.lungcan.2021.06.012	2021	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.	TP53
34195328	10.1016/j.jdcr.2021.05.014	2021	Bilateral auricular nodules: A peculiar presentation of systemic mantle cell lymphoma.	TP53
34218582	10.3760/cma.j.issn.0253-2727.2021.05.008	2021	[Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].	TP53
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	TP53
34226168	10.1016/j.clml.2021.06.006	2021	Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study.	TP53
34232939	10.1097/CAD.0000000000001094	2021	Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.	TP53
34233959	10.1158/1078-0432.CCR-21-0464	2021	Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <i>TP53-</i> and <i>BAX-</i>Dependent Manner.	TP53
34248972	10.3389/fimmu.2021.687458	2021	Targeting Bruton's Tyrosine Kinase in CLL.	TP53
34253131	10.1080/17474086.2021.1950529	2021	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.	TP53
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	TP53
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	TP53
34261406	10.1080/10428194.2021.1950710	2021	Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of <i>TP53</i> mutation and genetic complexity.	TP53
34267184	10.1038/s41419-021-03988-y	2021	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.	TP53
34269910	10.1007/s11912-021-01094-y	2021	Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.	TP53
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	TP53
34277785	10.21037/atm-21-2256	2021	Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.	TP53
34285380	10.1038/s41409-021-01418-3	2021	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.	TP53
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	TP53
34301750	10.1158/1078-0432.CCR-21-0715	2021	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.	TP53
34308104	10.1093/jncics/pkab007	2021	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.	TP53
34320163	10.1182/blood.2020006783	2021	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.	TP53
34323164	10.1080/10428194.2021.1950706	2021	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.	TP53
34339834	10.1016/j.critrevonc.2021.103430	2021	Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.	TP53
34345533	10.1080/2162402X.2021.1951019	2021	Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.	TP53
34349054	10.11406/rinketsu.62.721	2021	[Lineage switch from T-lymphoblastic leukemia to myeloid leukemia at relapse].	TP53
34350060	10.1080/2162402X.2021.1928365	2021	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.	TP53
34361036	10.3390/ijms22158268	2021	Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE).	TP53
34365011	10.1016/j.jmoldx.2021.07.013	2021	Practical Considerations for Using RNA Sequencing in Management of B-Lymphoblastic Leukemia: Malaysia-Singapore Acute Lymphoblastic Leukemia 2020 Implementation Strategy.	TP53
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	TP53
34376372	10.1016/j.clml.2021.07.007	2021	Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.	TP53
34381423	10.3389/fendo.2021.673908	2021	Case Report: Identification of Potential Prognosis-Related <i>TP53</i> Mutation and <i>BCL6-LPP</i> Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases.	TP53
34386317	10.1016/j.apsb.2020.10.018	2021	Natural compounds modulate the autophagy with potential implication of stroke.	TP53
34390161	10.1002/pbc.29285	2021	Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents.	TP53
34405395	10.1111/bjh.17749	2021	Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.	TP53
34406703	10.1002/ajh.26324	2021	The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.	TP53
34430143	10.7759/cureus.16534	2021	Clinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.	TP53
34440292	10.3390/genes12081118	2021	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	TP53
34478505	10.1182/bloodadvances.2021005083	2021	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	TP53
34496723	10.1080/10428194.2021.1957869	2021	Clinico-genomic profiling and clonal dynamic modeling of <i>TP53</i>-aberrant myelodysplastic syndrome and acute myeloid leukemia.	TP53
34497195	10.11406/rinketsu.62.1085	2021	[Molecular pathogenesis and treatment of chronic lymphocytic leukemia].	TP53
34500472	10.1182/bloodadvances.2021004528	2021	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.	TP53
34500495	10.1111/bjh.17830	2021	Adult T-cell leukaemia/lymphoma and the trouble with TP53.	TP53
34503286	10.3390/cancers13174476	2021	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.	TP53
34506616	10.1371/journal.pone.0257353	2021	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).	TP53
34511320	10.1016/j.clml.2021.07.022	2021	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).	TP53
34521752	10.1073/pnas.2105440118	2021	DNA damage-induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice.	TP53
34523970	10.1128/JVI.01459-21	2021	The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation.	TP53
34537440	10.1016/j.jtho.2021.07.035	2021	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.	TP53
34568060	10.3389/fonc.2021.729106	2021	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia.	TP53
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	TP53
34576319	10.3390/ijms221810157	2021	BH3 Mimetics in Hematologic Malignancies.	TP53
34589661	10.1200/PO.21.00112	2021	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.	TP53
34603753	10.17691/stm2021.13.3.04	2021	Asynchronous DNA Replication of Biallelically Expressed Genes in Human Peripheral Blood Lymphocytes as a Prognostic Sign of Cancer.	TP53
34625994	10.1002/ajh.26367	2021	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	TP53
34626359	10.1007/978-3-030-78311-2_8	2021	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.	TP53
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	TP53
34634383	10.1016/j.canlet.2021.10.006	2021	IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis.	TP53
34635181	10.1186/s40364-021-00330-8	2021	Deciphering genes associated with diffuse large B-cell lymphoma with lymphomatous effusions: A mutational accumulation scoring approach.	TP53
34646650	10.7759/cureus.17598	2021	An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.	TP53
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	TP53
34711913	10.1038/s41698-021-00235-7	2021	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers.	TP53
34729013	10.2147/OTT.S323700	2021	<i>ALK</i> Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report.	TP53
34754447	10.3892/mco.2021.2422	2021	Epstein-Barr virus infection mediated TP53 and Bcl-2 expression in nasopharyngeal carcinoma pathogenesis.	TP53
34771656	10.3390/cancers13215493	2021	High Expression of <i>PPM1D</i> Induces Tumors Phenotypically Similar to <i>TP53</i> Loss-of-Function Mutations in Mice.	TP53
34781193	10.1016/j.vetmic.2021.109269	2021	Mutations in the tumor suppressor gene p53 in cattle are associated with enzootic bovine leukosis.	TP53
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	TP53
34826411	10.1016/S2352-3026(21)00307-0	2021	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.	TP53
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	TP53
34885220	10.3390/cancers13236111	2021	Newborn Screening for the Detection of the <i>TP53</i> R337H Variant and Surveillance for Early Diagnosis of Pediatric Adrenocortical Tumors: Lessons Learned and Way Forward.	TP53
34893110	10.19746/j.cnki.issn.1009-2137.2021.06.015	2021	[Effect of RITA on TP53 Mutant Human Mantle Cell Lymphoma Cell Line and Its Mechanism].	TP53
34895266	10.1186/s13000-021-01173-5	2021	Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.	TP53
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	TP53
34926267	10.3389/fonc.2021.765544	2021	<i>SEPT6</i>_<i>TRIM33</i> Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.	TP53
34944936	10.3390/cancers13246316	2021	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, <i>TP53</i> Deletion, and a Poor Prognosis.	TP53
34956898	10.3389/fonc.2021.780085	2021	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.	TP53
35116331	10.21037/tcr-21-882	2021	Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study.	TP53
35122027	10.1038/s43018-021-00230-8	2021	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.	TP53
35126471	10.3389/fgene.2021.815679	2021	Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.	TP53
35844699	10.1002/jha2.261	2021	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.	TP53
31296581	10.3324/haematol.2019.219543	2020	Highly sensitive and specific <i>in situ</i> hybridization assay for quantification of <i>SOX11</i> mRNA in mantle cell lymphoma reveals association of <i>TP53</i> mutations with negative and low <i>SOX11</i> expression.	TP53
31433838	10.1093/ajcp/aqz133	2020	An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.	TP53
31462704	10.1038/s41388-019-0979-z	2020	Tumor-derived CK1α mutations enhance MDMX inhibition of p53.	TP53
31490284	10.1097/CAD.0000000000000824	2020	EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway.	TP53
31522287	10.1007/s00428-019-02658-x	2020	Lineage-negative lymphoma with a helper innate lymphoid cell phenotype.	TP53
31537689	10.3324/haematol.2018.214056	2020	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.	TP53
31559875	10.1177/1066896919878804	2020	Recurrent Pleomorphic Myxoid Liposarcoma in a Patient With Li-Fraumeni Syndrome.	TP53
31628428	10.1038/s41375-019-0602-x	2020	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.	TP53
31666375	10.1128/JVI.01553-19	2020	USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.	TP53
31697823	10.1182/blood.2019002220	2020	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.	TP53
31701788	10.1080/17474086.2020.1690987	2020	Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools.	TP53
31729120	10.1111/cas.14238	2020	TP53 alterations in relapsed childhood acute lymphoblastic leukemia.	TP53
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	TP53
31760435	10.1007/s00204-019-02623-2	2020	Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9.	TP53
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	TP53
31794893	10.1016/j.dnarep.2019.102754	2020	Loss of Setd4 delays radiation-induced thymic lymphoma in mice.	TP53
31804006	10.1002/cam4.2757	2020	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.	TP53
31822801	10.1038/s41379-019-0415-5	2020	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.	TP53
31842651	10.1080/10428194.2019.1702177	2020	Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.	TP53
31894386	10.1007/s00432-019-03116-6	2020	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.	TP53
31894535	10.1007/s12185-019-02810-y	2020	Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression.	TP53
31914529	10.3760/cma.j.issn.0529-5807.2020.01.004	2020	[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases].	TP53
31918102	10.1016/j.chemosphere.2019.125794	2020	Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R.	TP53
31964785	10.1158/1078-0432.CCR-19-3061	2020	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.	TP53
31965269	10.1007/s00277-020-03911-z	2020	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.	TP53
31975037	10.1007/s00428-020-02750-7	2020	Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.	TP53
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	TP53
32013644	10.1080/10428194.2020.1719089	2020	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes.	TP53
32016852	10.1007/s43440-019-00004-1	2020	Effect of new olivacine derivatives on p53 protein level.	TP53
32027255	10.19746/j.cnki.issn.1009-2137.2020.01.012	2020	[Analysis of Clinical Characteristics and Therapeutic Efficacy of Patients with Adult Acute Lymphoblastic Leukemia].	TP53
32033927	10.1016/j.clml.2019.10.009	2020	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.	TP53
32041553	10.1186/s12885-020-6599-8	2020	Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.	TP53
32044274	10.1016/j.clml.2020.01.003	2020	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.	TP53
32064880	10.4149/neo_2020_190307N194	2020	KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients.	TP53
32075226	10.3390/ijms21041309	2020	Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.	TP53
32077636	10.1111/1759-7714.13361	2020	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.	TP53
32103174	10.1038/s41586-020-2041-2	2020	DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis.	TP53
32119867	10.1016/j.jid.2019.12.041	2020	Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.	TP53
32139108	10.1016/j.arcmed.2020.02.005	2020	CpG Oligodeoxynucleotides Induces Apoptosis of Human Bladder Cancer Cells via Caspase-3-Bax/Bcl-2-p53 Axis.	TP53
32139296	10.1016/j.clml.2019.11.007	2020	Defining Acute Myeloid Leukemia Ontogeny in Older Patients.	TP53
32142900	10.1016/j.jmoldx.2020.02.004	2020	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.	TP53
32160292	10.1182/blood.2019002385	2020	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.	TP53
32161460	10.2147/IJN.S225142	2020	Synergistic Treatment of Tumor by Targeted Biotherapy and Chemotherapy via Site-Specific Anchoring of Aptamers on DNA Nanotubes.	TP53
32164276	10.3390/cancers12030642	2020	Precision Medicine Management of Chronic Lymphocytic Leukemia.	TP53
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	TP53
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	TP53
32191807	10.1182/bloodadvances.2019001396	2020	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.	TP53
32203146	10.1038/s41375-020-0795-z	2020	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study.	TP53
32223488	10.1080/10428194.2020.1742905	2020	Cytogenetically masked <i>CBFB-MYH11</i> fusion and concomitant <i>TP53</i> deletion in a case of acute myeloid leukemia with a complex karyotype.	TP53
32230928	10.3390/biom10040510	2020	An Extract of Transgenic Senna obtusifolia L. Hairy Roots with Overexpression of PgSS1 Gene in Combination with Chemotherapeutic Agent Induces Apoptosis in the Leukemia Cell Line.	TP53
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	TP53
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	TP53
32253666	10.1007/s12185-020-02867-0	2020	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	TP53
32255708	10.1080/10428194.2020.1747068	2020	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.	TP53
32257467	10.1155/2020/9185432	2020	Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion.	TP53
32272636	10.3390/cancers12040894	2020	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.	TP53
32277542	10.1002/gcc.22849	2020	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.	TP53
32299384	10.1186/s12885-020-06805-5	2020	Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.	TP53
32311893	10.3760/cma.j.issn.0253-2727.2020.03.008	2020	[The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion].	TP53
32316711	10.3779/j.issn.1009-3419.2020.101.17	2020	[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].	TP53
32317694	10.1038/s41598-020-63434-5	2020	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.	TP53
32321318	10.1080/13543784.2020.1760245	2020	Novel agents for mantle cell lymphoma: molecular rational and clinical data.	TP53
32322022	10.1038/s41379-020-0533-0	2020	Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.	TP53
32345625	10.1136/jitc-2019-000364	2020	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.	TP53
32362171	10.1080/10428194.2020.1759051	2020	Clinical outcomes and characteristics of patients with <i>TP53</i>-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.	TP53
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	TP53
32419250	10.1111/cpr.12826	2020	B-cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer.	TP53
32426239	10.1016/j.toxrep.2020.04.010	2020	MicroRNAs and Xenobiotic Toxicity: An Overview.	TP53
32431543	10.2147/CMAR.S242903	2020	Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population.	TP53
32453841	10.1182/bloodadvances.2020001466	2020	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.	TP53
32457845	10.3389/fonc.2020.00726	2020	The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients.	TP53
32472610	10.1002/hon.2750	2020	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.	TP53
32515564	10.36233/0507-4088-2020-65-2-87-94	2020	[Interferon-regulating activity of the CelAgrip drug and its influence on the formation of reactive oxygen species and expression of innate immunity genes in Burkitt's lymphome cells cultures.]	TP53
32519351	10.1111/bjh.16748	2020	Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).	TP53
32563740	10.1016/j.lungcan.2020.05.026	2020	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.	TP53
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	TP53
32580907	10.1016/j.clbc.2020.05.005	2020	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.	TP53
32581054	10.1136/jitc-2019-000218	2020	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.	TP53
32584970	10.1182/blood.2020005289	2020	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.	TP53
32589730	10.1182/bloodadvances.2020001696	2020	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.	TP53
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	TP53
32602002	10.1007/s12253-020-00864-6	2020	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma.	TP53
32620919	10.1038/s41379-020-0616-y	2020	Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.	TP53
32627089	10.1007/s10014-020-00373-z	2020	Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.	TP53
32632752	10.1007/s00109-020-01943-6	2020	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.	TP53
32649656		2020	Richter transformation of chronic lymphocytic leukemia in the era of novel agents.	TP53
32649887	10.1016/j.ccell.2020.06.002	2020	Immunogenomic Landscape of Hematological Malignancies.	TP53
32659728	10.1016/j.advms.2020.06.002	2020	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.	TP53
32695399	10.1186/s40364-020-00205-4	2020	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	TP53
32748433	10.1111/bjh.17023	2020	p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.	TP53
32751805	10.3390/cancers12082120	2020	Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.	TP53
32770099	10.1038/s41598-020-70310-9	2020	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.	TP53
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	TP53
32780847	10.1182/bloodadvances.2020001727	2020	Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.	TP53
32804454	10.1097/PAS.0000000000001512	2020	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	TP53
32825230	10.3390/genes11090960	2020	Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying <i>TP53</i> Molecular Alterations.	TP53
32838487	10.3779/j.issn.1009-3419.2020.102.14	2020	[Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].	TP53
32861280	10.1016/j.hoc.2020.06.001	2020	What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?	TP53
32862455	10.1111/bjh.17063	2020	A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.	TP53
32862873	10.1016/S2152-2650(20)30465-1	2020	The Problem of TP53-Mutant MDS/AML.	TP53
32862879	10.1016/S2152-2650(20)30470-5	2020	Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.	TP53
32871937	10.1097/MD.0000000000021938	2020	Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.	TP53
32872120	10.3390/jpm10030107	2020	Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, <i>ALK</i>-Positive, <i>TP53</i>-Mutant NSCLC.	TP53
32889036	10.1016/j.tiv.2020.104992	2020	Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.	TP53
32890601	10.1016/j.humpath.2020.08.008	2020	Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive Natural killer-cell leukemia/lymphoma.	TP53
32939265	10.1186/s40364-020-00222-3	2020	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.	TP53
32981916	10.3960/jslrt.20021	2020	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.	TP53
32988392	10.1186/s13000-020-01022-x	2020	Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.	TP53
32999452	10.1038/s41434-020-00194-x	2020	Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells.	TP53
33017727	10.1016/j.lungcan.2020.09.012	2020	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.	TP53
33060089	10.1136/bmjopen-2020-039168	2020	Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.	TP53
33061576	10.2147/CMAR.S260583	2020	The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells.	TP53
33093445	10.1038/s41419-020-03115-3	2020	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity.	TP53
33095873	10.1182/bloodadvances.2019001307	2020	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.	TP53
33116627	10.2147/OTT.S253758	2020	MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma.	TP53
33127875	10.1038/s41408-020-00376-1	2020	New directions for emerging therapies in acute myeloid leukemia: the next chapter.	TP53
33148342	10.1186/s13045-020-00982-3	2020	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.	TP53
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	TP53
33204162	10.2147/CMAR.S269624	2020	Characteristics and Management of <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma Patients.	TP53
33240649	10.7717/peerj.10335	2020	The rs78378222 prevalence and the copy loss of the protective allele A in the tumor tissue of diffuse large B-cell lymphoma.	TP53
33283700	10.19746/j.cnki.issn.1009-2137.2020.06.001	2020	[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing].	TP53
33290262	10.18632/aging.202146	2020	The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.	TP53
33333693	10.3760/cma.j.issn.0253-2727.2020.11.005	2020	[The effect of TP53 mutations on the clinical outcomes of Ph-negative B-acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].	TP53
33344238	10.3389/fonc.2020.584095	2020	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas.	TP53
33380880	10.3747/co.27.6795	2020	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.	TP53
33533212	10.36233/0507-4088-2020-65-5-5	2020	[Interferon-regulating activity of the celagrip antiviral drug and its influence on formation of reactive oxygen species and expression of innate immunity genes in the follicular lymphoma patients].	TP53
33585229	10.3389/fonc.2020.609409	2020	The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.	TP53
30255938	10.1002/ijc.31893	2019	Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma.	TP53
30592281	10.3892/mmr.2018.9793	2019	LncRNA BANCR participates in polycystic ovary syndrome by promoting cell apoptosis.	TP53
30702927	10.1096/fj.201801559RR	2019	AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells.	TP53
30843662	10.1002/cam4.2043	2019	Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.	TP53
30955249	10.1111/petr.13408	2019	Strong expression of p53 protein in bone marrow samples after hematopoietic stem cell transplantation indicates risk of relapse in pediatric acute lymphoblastic leukemia patients.	TP53
30962574	10.1038/s41556-019-0305-6	2019	ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway.	TP53
31056984	10.1080/10428194.2019.1608528	2019	MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival.	TP53
31101761	10.1158/0008-5472.CAN-18-1503	2019	Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis.	TP53
31128065	10.31557/APJCP.2019.20.5.1579	2019	TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population	TP53
31132650	10.1016/j.anndiagpath.2019.05.004	2019	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.	TP53
31207703	10.3760/cma.j.issn.0253-2727.2019.05.008	2019	[High-dose methylprednisolone with Rituximab and fresh frozen plasma in the treatment of six patients with B-cell lymphoproliferative disorders harboring TP53 abnormalities].	TP53
31208944	10.1016/S2352-3026(19)30104-8	2019	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.	TP53
31229158	10.1016/j.hoc.2019.03.002	2019	Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions.	TP53
31230491	10.1080/10428194.2019.1630619	2019	Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome.	TP53
31243098	10.1158/1535-7163.MCT-19-0105	2019	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.	TP53
31257681	10.1002/jcb.29143	2019	Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.	TP53
31268728	10.1080/17474086.2019.1639501	2019	Optimal management of mantle cell lymphoma in the primary setting.	TP53
31281315	10.3389/fimmu.2019.01382	2019	The Molecular Evolution and Functional Divergence of Lamprey Programmed Cell Death Genes.	TP53
31285322	10.1073/pnas.1905305116	2019	Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.	TP53
31289210	10.3324/haematol.2018.205849	2019	<i>TP53, ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.	TP53
31316614	10.3892/etm.2019.7674	2019	miRNA-125a-5p inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting TP53 regulated inhibitor of apoptosis 1 and Bcl-2-like-2 protein.	TP53
31317311	10.1007/s00428-019-02608-7	2019	Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.	TP53
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	TP53
31339741	10.1089/dna.2018.4520	2019	Recombinant Pierisin-5 Induces Apoptosis and Differential Expression of Bcl-2, Bax, and p53 in Human Cancer Cells.	TP53
31343754	10.1002/ddr.21573	2019	Anticancer activity of newly synthesized 1,1-disubstituted cyclohexane-1-carboxamides: in vitro caspases mediated apoptosis activators in human cancer cell lines and their molecular modeling.	TP53
31352982	10.1016/j.path.2019.03.012	2019	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.	TP53
31359442	10.1002/hon.2657	2019	CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.	TP53
31371221	10.1016/j.clml.2019.03.002	2019	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.	TP53
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	TP53
31406302	10.1038/s41568-019-0179-8	2019	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.	TP53
31411343	10.1002/path.5333	2019	Genomic characterisation of breast fibroepithelial lesions in an international cohort.	TP53
31433581	10.3349/ymj.2019.60.9.832	2019	miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.	TP53
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	TP53
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	TP53
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	TP53
31444835	10.1111/cas.14177	2019	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.	TP53
31473630	10.1136/jclinpath-2019-205895	2019	Somatic <i>SF3B1</i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia.	TP53
31475375	10.1002/hon.2674	2019	m7FLIPI and targeted sequencing in high-risk follicular lymphoma.	TP53
31512258	10.1002/ajh.25638	2019	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.	TP53
31542870	10.1007/s11523-019-00673-1	2019	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.	TP53
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	TP53
31607305	10.19746/j.cnki.issn.1009-2137.2019.05.023	2019	[Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].	TP53
31644328	10.1200/JCO.19.01694	2019	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.	TP53
31648313	10.1182/bloodadvances.2019000051	2019	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.	TP53
31648477	10.3760/cma.j.issn.0253-2727.2019.09.008	2019	[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].	TP53
31652456	10.1042/BSR20191357	2019	The inhibition of tumor protein p53 by microRNA-151a-3p induced cell proliferation, migration and invasion in nasopharyngeal carcinoma.	TP53
31693904	10.1016/j.celrep.2019.09.071	2019	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.	TP53
31699989	10.1038/s41467-019-13002-x	2019	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.	TP53
31753813	10.1101/mcs.a004630	2019	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer.	TP53
31776787	10.1007/s11864-019-0684-8	2019	Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.	TP53
31780660	10.1038/s41408-019-0259-8	2019	Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.	TP53
31808882	10.1182/hematology.2019000011	2019	Molecular profiling and management of mantle cell lymphoma.	TP53
31839919	10.1177/2040620719891356	2019	Emerging treatment options for patients with p53-pathway-deficient CLL.	TP53
31856440	10.3760/cma.j.issn.0253-2727.2019.11.006	2019	[Clinical prognosis analysis of patients with double hit multiple myeloma].	TP53
31891126	10.1016/j.cdtm.2019.08.001	2019	Cross-talk between Myc and p53 in B-cell lymphomas.	TP53
32397023	10.3760/cma.j.issn.0253-2727.2019.07.010	2019	[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].	TP53
27859003	10.1111/bjh.14431	2018	Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.	TP53
28902083	10.1097/MPH.0000000000000948	2018	Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.	TP53
29115375	10.3892/ijmm.2017.3205	2018	Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.	TP53
29196411	10.1182/blood-2017-07-797019	2018	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.	TP53
29300620	10.1200/JCO.2017.75.5215	2018	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.	TP53
29336471	10.3892/ijmm.2018.3392	2018	Neuroprotective effects of p53/microRNA‑22 regulate inflammation and apoptosis in subarachnoid hemorrhage.	TP53
29338567	10.1080/10428194.2017.1422864	2018	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.	TP53
29346503	10.1093/carcin/bgy001	2018	p53β: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up.	TP53
29653964	10.1182/blood-2017-09-806679	2018	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.	TP53
29661169	10.1186/s12885-018-4304-y	2018	RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas.	TP53
29789628	10.1038/s41467-018-04356-9	2018	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.	TP53
29790592	10.1002/hep.30098	2018	Hepatitis B Virus-Upregulated LNC-HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity.	TP53
29794145	10.3324/haematol.2018.194399	2018	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of <i>TP53</i> mutations in mantle cell lymphoma.	TP53
29885057	10.1002/path.5110	2018	Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.	TP53
29885407	10.1016/j.humpath.2018.05.026	2018	TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression.	TP53
30086334	10.1016/j.humpath.2018.07.030	2018	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.	TP53
30165392	10.1093/annonc/mdy333	2018	Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.	TP53
30297390	10.1136/jim-2018-000804	2018	Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.	TP53
27268868	10.1080/10428194.2016.1187276	2017	Ability to downregulate the level of cyclin-dependent kinase inhibitor p27<sup>Kip1</sup> after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.	TP53
27619989	10.1007/s10689-016-9931-3	2017	Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.	TP53
27721412	10.1038/onc.2016.360	2017	Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.	TP53
27739436	10.1038/modpathol.2016.178	2017	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.	TP53
27993575	10.1016/j.humpath.2016.12.007	2017	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.	TP53
28003275	10.1101/cshperspect.a026286	2017	<i>TP53</i> Mutations in Hypodiploid Acute Lymphoblastic Leukemia.	TP53
28251968	10.7868/S0026898416060227	2017	[Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma].	TP53
28281555	10.1038/modpathol.2017.5	2017	NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.	TP53
28284458	10.1016/j.blre.2017.03.001	2017	p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.	TP53
28301507	10.1371/journal.pone.0173171	2017	TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.	TP53
28369138	10.1371/journal.pone.0174809	2017	TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.	TP53
28474779	10.1002/ajh.24778	2017	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.	TP53
28484276	10.1038/s41598-017-01800-6	2017	Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.	TP53
28551630	10.21873/anticanres.11646	2017	Expression and Prognostic Significance of <i>EP300</i>, <i>TP53</i> and <i>BAX</i> in Clear Cell Renal Cell Carcinoma.	TP53
28557976	10.1038/bjc.2017.152	2017	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.	TP53
28614910	10.1002/ijc.30838	2017	TP53 mutation and survival in aggressive B cell lymphoma.	TP53
28654064	10.3791/55703	2017	Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay.	TP53
28687222	10.1016/j.clml.2017.06.003	2017	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.	TP53
28791403	10.3892/or.2017.5891	2017	Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.	TP53
28819011	10.1182/blood-2017-04-779736	2017	<i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.	TP53
28901386	10.3892/mmr.2017.7379	2017	Aloin promotes A549 cell apoptosis via the reactive oxygen species‑mitogen activated protein kinase signaling pathway and p53 phosphorylation.	TP53
29126407	10.1186/s12885-017-3760-0	2017	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.	TP53
25915849	10.1038/onc.2015.88	2016	Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.	TP53
26209050	10.1007/s12094-015-1338-3	2016	Potential impact of (rs 4645878) BAX promoter -248G&gt;A and (rs 1042522) TP53 72Arg&gt;pro polymorphisms on epithelial ovarian cancer patients.	TP53
26315382	10.1016/j.critrevonc.2015.08.006	2016	TP53 dysfunction in diffuse large B-cell lymphoma.	TP53
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	TP53
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	TP53
26648441	10.3892/mmr.2015.4606	2016	Effects of miR‑590 on oxLDL‑induced endothelial cell apoptosis: Roles of p53 and NF‑κB.	TP53
26709646	10.2741/E751	2016	The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.	TP53
26754533	10.3109/10428194.2015.1124992	2016	The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.	TP53
26904937	10.1016/j.celrep.2016.01.059	2016	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.	TP53
26909609	10.18632/oncotarget.7539	2016	Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity.	TP53
26982726	10.1038/nature17157	2016	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.	TP53
26992948	10.3324/haematol.2015.137059	2016	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.	TP53
27101868	10.1186/s40478-016-0307-6	2016	TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.	TP53
27229929	10.1186/s12885-016-2374-2	2016	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	TP53
27284738	10.1038/bcj.2016.41	2016	p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.	TP53
27351221	10.18632/oncotarget.10268	2016	Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.	TP53
27542204	10.18632/oncotarget.11297	2016	Nucks1 synergizes with Trp53 to promote radiation lymphomagenesis in mice.	TP53
27559048	10.4049/jimmunol.1501989	2016	The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.	TP53
27622827	10.1016/j.clml.2016.08.016	2016	Aberrant p15, p16, p53, and DAPK Gene Methylation in Myelomagenesis: Clinical and Prognostic Implications.	TP53
27627705	10.1111/cas.13080	2016	EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.	TP53
27698449	10.1038/srep34578	2016	Cr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes.	TP53
27825110	10.18632/oncotarget.13065	2016	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.	TP53
27906186	10.1038/cddis.2016.382	2016	Preimplantation factor is an anti-apoptotic effector in human trophoblasts involving p53 signaling pathway.	TP53
28005077	10.1038/cddis.2016.430	2016	Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.	TP53
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	TP53
24898668	10.3109/10428194.2014.929673	2015	Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.	TP53
24925209	10.3109/10428194.2014.930850	2015	Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma.	TP53
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	TP53
25430047	10.1111/bjh.13237	2015	Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.	TP53
25573202	10.3109/10428194.2014.1003559	2015	Point mutations in TP53 but not in p15(Ink4b) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma.	TP53
25589462	10.1007/s13277-014-3035-1	2015	Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.	TP53
25590240	10.1080/15384101.2015.1004935	2015	PCDH10, a novel p53 transcriptional target in regulating cell migration.	TP53
25641428	10.3109/10428194.2015.1011641	2015	How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?	TP53
25646413	10.1073/pnas.1500010112	2015	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.	TP53
25692307	10.1080/15384047.2014.1002698	2015	Inauhzin(c) inactivates c-Myc independently of p53.	TP53
25695150	10.3892/mmr.2015.3370	2015	Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53.	TP53
25775024	10.1186/s12885-015-1048-9	2015	Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.	TP53
25915824	10.1038/leu.2015.101	2015	MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.	TP53
26022239	10.1182/blood-2015-02-628792	2015	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.	TP53
26082451	10.1182/blood-2014-11-611194	2015	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.	TP53
26106001	10.3960/jslrt.55.13	2015	Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.	TP53
26185311	10.1309/AJCPW83OXPYKPEEN	2015	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.	TP53
26232254	10.1016/j.mrgentox.2015.05.011	2015	Relationships between p53 status, apoptosis and induction of micronuclei in different human and mouse cell lines in vitro: Implications for improving existing assays.	TP53
26324762	10.18632/oncotarget.4319	2015	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.	TP53
26556860	10.18632/oncotarget.5715	2015	The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.	TP53
26638586		2015	The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).	TP53
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	TP53
26720344	10.1038/cddis.2015.358	2015	Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.	TP53
24232982	10.1007/s10120-013-0313-3	2014	Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.	TP53
24240203	10.1038/leu.2013.345	2014	Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.	TP53
24248600	10.1128/MCB.01011-13	2014	p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3.	TP53
24619762	10.1309/AJCPPHMZ6VHF0WQV	2014	p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.	TP53
24619868	10.1002/gcc.22163	2014	Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.	TP53
24628257	10.1179/1607845414Y.0000000153	2014	Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells via p53 and p21Waf1/Cip1 up-regulation.	TP53
24642368	10.1016/j.prp.2014.02.004	2014	Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.	TP53
24652995	10.1182/blood-2013-10-532390	2014	p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling.	TP53
24787013	10.1038/cddis.2014.150	2014	Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.	TP53
24829203	10.1182/blood-2014-02-558833	2014	TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.	TP53
24852242	10.1016/j.anndiagpath.2014.03.006	2014	Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.	TP53
24911057	10.1371/journal.pone.0099255	2014	Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis.	TP53
25070816		2014	L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.	TP53
25203442	10.1371/journal.pone.0107047	2014	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	TP53
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	TP53
25842861		2014	[Linkage disequilibrium and haplotypes of rs1042522, rs1625895 and rs17878362 gene TP53 markers in patients with diffuse large B-cell lymphoma].	TP53
22699455	10.1038/leu.2012.155	2013	Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.	TP53
22801382	10.1038/leu.2012.198	2013	Partial 17q gain resulting from isochromosomes, unbalanced translocations and complex rearrangements is associated with gene overexpression, older age and shorter overall survival in high hyperdiploid childhood acute lymphoblastic leukemia.	TP53
23121011	10.3109/10428194.2012.745527	2013	TP53 mutation is rare in primary myelofibrosis.	TP53
23255406	10.1002/pbc.24417	2013	Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.	TP53
23269799	10.1128/JVI.03081-12	2013	B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes.	TP53
23358872	10.1593/neo.121362	2013	The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT1.	TP53
23403321	10.3324/haematol.2012.076786	2013	TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.	TP53
23483263	10.3892/ijo.2013.1853	2013	cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.	TP53
23487038	10.1242/jcs.118174	2013	BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.	TP53
23515929	10.1182/blood-2012-12-471722	2013	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.	TP53
23528269	10.18632/oncotarget.933	2013	Growth factor independence 1 (Gfi1) as a regulator of p53 activity and a new therapeutical target for ALL.	TP53
23589839	10.1073/pnas.1208530110	2013	Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.	TP53
23608226	10.1016/j.ajpath.2013.01.025	2013	Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK/T-cell lymphoma.	TP53
23626008	10.1136/jclinpath-2013-201454	2013	p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type.	TP53
23653000	10.1007/s11033-013-2551-1	2013	CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL).	TP53
23733769	10.1200/JCO.2012.46.3711	2013	Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.	TP53
23745682	10.1089/dna.2012.1900	2013	Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population.	TP53
23852341	10.1038/nm.3247	2013	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.	TP53
23982177	10.1182/blood-2012-12-473702	2013	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.	TP53
23991992	10.7314/apjcp.2013.14.7.4295	2013	Clinical significance of serum p53 and epidermal growth factor receptor in patients with acute leukemia.	TP53
24036547	10.4161/cc.26299	2013	Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations.	TP53
24122997		2013	Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.	TP53
24294363		2013	Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.	TP53
21804610	10.1038/onc.2011.331	2012	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding.	TP53
21823831	10.3109/10428194.2011.608453	2012	Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.	TP53
22047081	10.1089/dna.2011.1314	2012	Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.	TP53
22057359	10.1007/s12032-011-0096-5	2012	TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.	TP53
22156152	10.1177/1538574411422277	2012	p53 gene therapy modulates signal transduction in the apoptotic and cell cycle pathways downregulating neointimal hyperplasia.	TP53
22220854	10.3109/10428194.2011.654115	2012	p53 protein expression in chronic lymphocytic leukemia.	TP53
22235305	10.1371/journal.pone.0029541	2012	miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.	TP53
22263566	10.3109/10428194.2012.658794	2012	Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.	TP53
22266868	10.1038/onc.2011.648	2012	Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival.	TP53
22275381	10.1182/blood-2011-11-366062	2012	Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.	TP53
22280536	10.3109/10428194.2012.660630	2012	Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.	TP53
22315488	10.3324/haematol.2011.055715	2012	The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.	TP53
22323293	10.1091/mbc.E11-06-0524	2012	Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors.	TP53
22384858	10.1111/j.1365-2133.2012.10918.x	2012	The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.	TP53
22502699	10.7314/apjcp.2012.13.1.349	2012	TP53 codon 72 polymorphism and risk of acute leukemia.	TP53
22607702	10.1016/j.humpath.2012.02.010	2012	Immunohistochemical and oncogenetic analyses of the esophageal basaloid squamous cell carcinoma in comparison with conventional squamous cell carcinomas.	TP53
22845047	10.1111/j.1365-2141.2012.09243.x	2012	TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.	TP53
22855598	10.1182/blood-2012-03-419937	2012	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.	TP53
22927405	10.1073/pnas.1205664109	2012	Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses.	TP53
22933706	10.1158/1535-7163.MCT-12-0135	2012	Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.	TP53
22945289	10.1002/eji.201242530	2012	ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis.	TP53
22955915	10.1182/blood-2012-05-433334	2012	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	TP53
22965953	10.1200/JCO.2011.40.7783	2012	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	TP53
23029260	10.1371/journal.pone.0045820	2012	p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.	TP53
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	TP53
23053979	10.1007/s11033-012-1978-0	2012	p53 Codon 72 arginine/proline polymorphism and cancer in Sudan.	TP53
21127431	10.1097/MPH.0b013e3181edf543	2011	The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.	TP53
21174181	10.1007/s12253-010-9335-x	2011	Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China.	TP53
21192060	10.1002/cncr.25826	2011	Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.	TP53
21205967	10.1001/jama.2010.1919	2011	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	TP53
21345471	10.1016/j.medcli.2010.11.011	2011	[Li-Fraumeni syndrome].	TP53
21386967	10.1371/journal.pone.0017012	2011	Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.	TP53
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	TP53
21463115	10.3109/10428194.2011.557454	2011	Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population.	TP53
21487039	10.1158/0008-5472.CAN-10-4300	2011	Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.	TP53
21546086	10.1016/j.leukres.2011.04.001	2011	No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma.	TP53
21619452	10.3109/10799893.2011.578140	2011	Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.	TP53
21720382	10.1038/leu.2011.162	2011	Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.	TP53
21738398		2011	Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva.	TP53
21747090	10.1200/JCO.2011.34.8144	2011	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	TP53
21750659	10.1593/neo.11542	2011	Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2.	TP53
21764855	10.1101/gad.2069311	2011	Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.	TP53
21852537	10.1101/gad.16722111	2011	Validation of MdmX as a therapeutic target for reactivating p53 in tumors.	TP53
21888455	006	2011	Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.	TP53
21903579	10.1074/jbc.M111.272336	2011	p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.	TP53
22056774	10.1038/nsmb.2142	2011	Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein.	TP53
19586936	10.3324/haematol.2009.007526	2010	Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.	TP53
20126990	10.3892/ijo_00000545	2010	Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.	TP53
20130056	10.1128/JVI.01321-09	2010	Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.	TP53
20181625		2010	Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.	TP53
20346139	10.1186/1746-1596-5-19	2010	Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.	TP53
20352431	10.1007/s00277-010-0945-x	2010	Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.	TP53
20369488		2010	[Expression and significance of P53 and P21 in nasal NK/T-cell lymphoma].	TP53
20457152	10.1016/j.yexcr.2010.04.030	2010	Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells.	TP53
20575032	10.1002/ajh.21738	2010	A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.	TP53
20734458	10.1002/ajh.21834	2010	Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma.	TP53
20807096	10.3109/10428194.2010.502584	2010	PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.	TP53
20811663	10.3892/or.2010.851	2010	p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma.	TP53
21131755	10.4103/0019-509X.73576	2010	Detection of B cell lymphoma 2, tumor protein 53, and FAS gene transcripts in blood cells of patients with breast cancer.	TP53
18540692	10.2350/07-11-0378.1	2009	Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series.	TP53
18706692	10.1016/j.leukres.2008.06.022	2009	TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.	TP53
18830263	10.1038/leu.2008.240	2009	Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.	TP53
18972317	10.1080/00313020802441683	2009	Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene.	TP53
19029147	10.3324/haematol.13533	2009	Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.	TP53
19046801	10.1016/j.canlet.2008.10.029	2009	TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.	TP53
19225536	10.1038/leu.2008.348	2009	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.	TP53
19234440	10.1038/modpathol.2009.2	2009	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	TP53
19286999	10.1182/blood-2008-06-160168	2009	NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.	TP53
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	TP53
19347736	10.1080/10428190902763517	2009	MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.	TP53
19347737	10.1080/10428190902763533	2009	Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.	TP53
19451550	10.1182/blood-2009-02-204883	2009	Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation.	TP53
19452712		2009	[Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells].	TP53
19500100	10.1111/j.1365-2141.2009.07739.x	2009	The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.	TP53
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	TP53
19589272	10.1177/147323000903700332	2009	Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastic tumours.	TP53
19594747	10.1111/j.1365-2141.2009.07791.x	2009	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	TP53
19608668	10.3324/haematol.2009.007260	2009	Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.	TP53
19650989		2009	[Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma].	TP53
19723045	10.1111/j.1749-6632.2009.04686.x	2009	Transforming growth factor-beta1 and regulators of apoptosis.	TP53
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	TP53
19799083		2009	[Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma].	TP53
19837266	10.1016/j.cancergencyto.2009.05.009	2009	TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.	TP53
19941740	10.1179/102453309X12473408860389	2009	Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia.	TP53
20160358	10.4103/0973-1482.59901	2009	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.	TP53
17728781	10.1038/sj.leu.2404929	2008	Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.	TP53
17982487	10.1038/sj.onc.1210901	2008	Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.	TP53
18165800	10.1038/modpathol.3800993	2008	Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation.	TP53
18297513	10.1080/10428190801950041	2008	Accumulating evidence for a role of p53 in multiple drug resistant acute myeloid leukemia.	TP53
18433491	10.1186/1471-2407-8-116	2008	MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.	TP53
18467333	10.1074/jbc.M709695200	2008	Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.	TP53
18559976	10.1182/blood-2008-01-129783	2008	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.	TP53
18593934	10.1158/0008-5472.CAN-07-5876	2008	c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.	TP53
18616513	10.1111/j.1600-0609.2008.01113.x	2008	Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.	TP53
18628487	10.1182/blood-2008-05-154013	2008	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.	TP53
18669630	10.1074/jbc.M804433200	2008	A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection.	TP53
18813817		2008	An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication.	TP53
18949611	10.1080/10428190802345902	2008	Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.	TP53
16988840	10.1007/s00432-006-0152-2	2007	Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis.	TP53
17364023	10.1172/JCI30945	2007	Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.	TP53
17545546	10.1158/1078-0432.CCR-06-2581	2007	Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.	TP53
17587242	10.1111/j.1440-1827.2007.02119.x	2007	Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma.	TP53
17609875	10.1007/s10238-007-0124-0	2007	Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.	TP53
17613764	10.1080/10428190701402903	2007	Characterization of genetic changes in MCL by interphase FISH on tissue sections.	TP53
17692879	10.1016/j.toxicon.2007.06.018	2007	A crystalline compound (BM-ANF1) from the Indian toad (Bufo melanostictus, Schneider) skin extract, induced antiproliferation and apoptosis in leukemic and hepatoma cell line involving cell cycle proteins.	TP53
17693666	10.1093/carcin/bgm172	2007	Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.	TP53
17695524		2007	Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.	TP53
17881637	10.1182/blood-2007-02-072082	2007	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.	TP53
17890905	10.4161/cc.6.18.4730	2007	p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas.	TP53
17990259	10.1002/elps.200600831	2007	Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.	TP53
18365550		2007	Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.	TP53
16249378	10.1182/blood-2005-04-1629	2006	BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.	TP53
16331255	10.1038/sj.onc.1209282	2006	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.	TP53
16432227	10.1073/pnas.0507367103	2006	ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.	TP53
16455055	10.1016/j.bbrc.2006.01.036	2006	Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins.	TP53
16532027	10.1038/sj.onc.1209480	2006	Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.	TP53
16569765	10.1182/blood-2006-01-0067	2006	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.	TP53
16595680	10.1074/jbc.M513810200	2006	KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia.	TP53
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	TP53
16773719	10.3748/wjg.v12.i22.3602	2006	Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.	TP53
17065008	10.1080/10428190600667721	2006	Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.	TP53
17069461	10.1371/journal.ppat.0020116	2006	EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.	TP53
17107393	10.1111/j.1365-2133.2006.07527.x	2006	Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides.	TP53
15632067	10.1128/MCB.25.2.661-670.2005	2005	Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression.	TP53
15713979		2005	The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.	TP53
15878620	10.1016/j.leukres.2005.04.006	2005	Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.	TP53
15902285	10.1038/sj.leu.2403802	2005	A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.	TP53
15969767	10.1186/1471-2172-6-12	2005	Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.	TP53
16094360	10.1038/nature03845	2005	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	TP53
16112647	10.1016/j.bbrc.2005.08.026	2005	Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53.	TP53
16131817	10.1159/000087980	2005	TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases.	TP53
14994997	10.1615/jenvpathtoxoncol.v23.i1.70	2004	p53 binding to target sites is dynamically regulated before and after ionizing radiation-mediated DNA damage.	TP53
15061204	10.1080/1042819031000147009	2004	Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.	TP53
15291355	10.1080/10428190310001638878	2004	Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese.	TP53
15351976	10.1002/cyto.b.20013	2004	Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.	TP53
15378026	10.1038/sj.onc.1207908	2004	Wild-type p53 activates SAP expression in lymphoid cells.	TP53
15577913	10.1038/nature03147	2004	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	TP53
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	TP53
12592393	10.1038/sj.onc.1206236	2003	Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients.	TP53
12749011	10.1002/ajh.10333	2003	Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.	TP53
12808109	10.1128/MCB.23.13.4713-4727.2003	2003	p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.	TP53
12824925	10.1111/j.1349-7006.2003.tb01436.x	2003	Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.	TP53
12854888	10.1080/1042819031000067620	2003	Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.	TP53
12901974	10.1016/s0301-472x(03)00159-0	2003	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth.	TP53
14559824		2003	PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.	TP53
14673037	10.1200/JCO.2003.12.042	2003	TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.	TP53
14689061		2003	Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.	TP53
11818669	10.1159/000046626	2002	Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas.	TP53
11839577	10.1016/S0002-9440(10)64876-6	2002	Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.	TP53
11914273	10.1101/gad.929302	2002	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.	TP53
11999565	10.1080/1042819029000611610	2002	Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.	TP53
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	TP53
12217802		2002	Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.	TP53
12235242	10.1124/jpet.102.037192	2002	DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells.	TP53
12421820	10.1074/jbc.C200578200	2002	Acetylation of p53 inhibits its ubiquitination by Mdm2.	TP53
11733360	10.1016/S0002-9440(10)63061-1	2001	p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.	TP53
11764099	10.1080/088800101753328466	2001	MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors.	TP53
11949843		2001	Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study.	TP53
9419979	10.1038/sj.onc.1201668	1997	Drastic genetic instability of tumors and normal tissues in Turcot syndrome.	TP53
9444950	10.1038/sj.onc.1201492	1997	Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53.	TP53
7753047	10.1016/0161-5890(95)00005-y	1995	Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.	TP53
8221626	10.1016/0304-3835(93)90256-9	1993	Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.	TP53
1303181	10.1093/hmg/1.3.207	1992	A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.	TP53
1437144		1992	p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.	TP53
1737852	10.1172/JCI115630	1992	Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.	TP53
1915267	10.1002/j.1460-2075.1991.tb07837.x	1991	p53 is frequently mutated in Burkitt's lymphoma cell lines.	TP53
